Fundz

Fundz Deep Dive

Everything you need to win NGM Bio — in one platform.

Who to reach, what to say, and why now on NGM Bio — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on NGM Bio — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

NGM Bio and KdT Ventures Enter Worldwide License Agreement for NGM313

Dec 19, 2024•over 1 year ago

Contract Type

agreement

San FranciscoBiotechnologyHealth CareTherapeutics

Description

NGM Bio and KdT Ventures have entered into a worldwide license agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho agonist drug candidate. NGM Bio will receive up to $608 million in upfront and potential development, regulatory and sales milestone payments, as well as tiered royalties on net sales and equity in the new company. KdT Ventures has formed a new company to develop NGM313 in a rare disease indication.

Company Information

Company

NGM Bio

Location

San Francisco, California, United States

About

NGM Bio is a biotech company focused on developing innovative therapies for serious, rare conditions with significant unmet patient needs. The company aims to address underlying biological mechanisms of diseases such as primary sclerosing cholangitis (PSC) and hyperemesis gravidarum (HG) to provide potential treatment options. NGM Bio is committed to advancing clinical development efforts to benefit patients with rare conditions.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for NGM Bio's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.